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Summary A nationwide mammographic screening for breast cancer was started in Finland in 1987. During
the first 2 years of the organised screening programme, 126,000 women were invited. Most of them (103,000)
belonged to the birth year cohort in the 50-59 years' age groups. Among the 112,000 screenees, 418 cancers
(0.4%) were found. Specificity of the test was about 96%. The screening prevalance was 2.4 times the annual
incidence and a minimum estimate for the detection rate among those invited was 1.6 times that among those
not invited. These estimates indicate a relatively low test and programme sensitivity. The final effectiveness of
a public health policy cannot be predicted on the basis of limited preventive trials, and there is need to
evaluate also a public health policy by experimental means.
The first randomised preventive trial on screening for breast
cancer based on mammography stems from the 1960's (Sha-
piro et al., 1988). The HIP-study indicates that about every
third death from breast cancer can be prevented by mammo-
graphy. Later, similar results from Sweden (Tabar et al.,
1985; 1987) and from the Netherlands (Collette et al., 1984;
Verbeek et al., 1984) were published. Recently, however,
more negative results have appeared. In Sweden (Andersson
et al., 1988) and in the UK (Chamberlain et al., 1988;
Roberts et al., 1990) the mortality from breast cancer in the
screened population was only slightly different from that
among the controls several years after the start of the study.
In Finland a nation-wide population-based screening pro-
gramme was started at the beginning of 1987. Mammo-
graphy-based screening for breast cancer was gradually
implemented using an experimental scheme (Hakama, 1988).
In birth cohorts recommended by the National Board of
Health, women are individually identified and invited for
screening. The programme starts between the ages of 50 and
59 years and will later probably also cover the ages from 60
to 69 years. The same women will be rescreened every 2
years. The programme is recommended to start with cohorts
born even years and to have the odd year born women as
controls for the first years of operation of the programme.
The Cancer Society of Finland has established 11 regional
mammography screening centres. A centralised Mass Screen-
ing Registry for identification, invitation and follow-up of the
cohorts operates within the Finnish Cancer Registry. The
National Population Registry, national registration of deaths,
and cancer registrations are linked with the screening results
by the Mass Screening Registry.
Each person belonging to the selected cohorts receives a
letter of invitation with a personal appointment time as well
as details of the screening procedure. Every participant
receives a letter notifying her whether the screen is positive or
negative. No reminders are sent to the non-attenders.
A cranio-caudal and anterior-posterior two-view mammo-
graphy is used. Two radiologists interpret mammograms and
one of them carries out further examinations in screen posi-
tive cases.
This study reports the findings for the first 2 years of this
nationwide public health policy and makes predictions on its
effectiveness.
Results
During the first year of operation, 1987, the programme
organised by the Cancer Society of Finland covered 254 out
of 460 municipalities. In 1988 the number of municipalities
covered was 286. The cohorts born in 1928, 1932, and 1936
were recommended to be screened in 1987 and those born
1930, 1934, and 1938 in 1988. The size of each cohort was
about 28,000. During the first year, 84% of the municipalities
followed these guidelines. The total number of invitations in
1987 and 1988 was 126,000 and the number of participants
was 112,000 (88.4%). Four and half per cent were screen
positives. The proportion of fine needle biopsies done was
0.9%, and 418 (0.4%) cancers were confirmed (Table I). The
total cost was about $50 per women screened.
In the age group 50 to 59 years there were 270,000 women.
Of those 103,000 women were invited and of those 81,000
belonged to the even born cohorts (Table II). The proportion
of cancers diagnosed among those invited was 0.31% and
among those not invited it was 0.20% per year. The ratio of
detection rate among those invited to rate among those not
invited was 1.6.
The ratio of screening prevalence of those attending in
1987-88 to age specific incidence in 1985-1986 for total
Finland was 2.4. Assuming that true sensitivity exceeded
10%, the specificity was more than 96%. Altogether 30
radiologists were involved; they were divided into 14 regions.
The proportion of false positives of all those screened varied
from 2.3 to 6.0% by region, and the ratio of screening
prevalence to breast cancer incidence (Finland 1985-86 as
reference) varied from 1.6 to 5.0 (Figure 1).
Table I The organised screening for breast cancer in Finland
1987 1988 Total
Number ofinvitations 58,141 68,114 126,255
Attenders Number 51,406 60,276 111,682
Per cent 88.4 88.5 88.5
Screen positives Number 2,655 2,425 5,080
Per cent 5.14 4.02 4.55
Cytologically positive Number 520 478 998
Per cent 1.01 0.79 0.89
Histologically malignant Number 191 227 418
Per cent 0.37 0.38 0.37
False screen positives Number 2,464 2,198 4,662
Per cent 4.79 3.65 4.17
TableH Numbersandproportions(%)ofbreastcancercasesdetected
at the age of 50-59 years by birth cohort and invitation to attend the
screening, Finland 1987-1988
Invited
Even Odd
cohort cohort
Not invited
Even Odd
cohort cohort
Women 81,246 21,571 190,466 249,018
Number of cancers 244 76 446 443
Proportion (%) 0.30 0.35 0.23 0.18
Correspondence: M. Hakama, Finnish Cancer Registry, Liisankatu
21 B, SF-00170 Helsinki, Finland.
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Figure 1 Scireening for breast cancer in Finland 1987-1988.
Correlation between the false positive rate and the ratio of
screening prevalence to incidence in 14 central hospital districts.
Discussion
Finland is to our knowledge the first country to implement
nation-wide screening for breast cancer as a public health
policy. The :participation rate, 88%, is among the highest
reported anywhere, and the programme was successfully
carried out. An organised programme (Hakama et al., 1985)
was chosen because of the larger effect at lower cost and
because of the possibility of more reliable evaluation as
compared to opportunistic screening. The screening pro-
gramme was implemented as an experiment based on munici-
pality specific birth cohorts (Hakama, 1988). The programme
started gradually and first covered women born in even-year
birth cohorts. The odd years adjacent to the screened cohorts
remained as controls during the period the programme
expanded. Future success of the design will depend on the
motivation of the municipalities to comply with the National
Board of Health's guidelines on screening. In some munici-
palities screening of the cohorts designed to remain as con-
trols caused deviations from the experimental plan. Even if
such deviations were in future serious enough to prevent
experimental evaluation, the non-experimental cohort design
is still applicable as the second best alternative. Those invited
are identified, their screening history is known, and they are
monitored for deaths through the Mass Screening Registry.
Compared to the expenses of breast cancer detection and
treatment, the evaluation costs are marginal and much
smaller than the costs of any retrospective attempt to esti-
mate reliably the effectiveness of the programme by conven-
tional methods.
Opportunistic screening, as well as everyday clinical prac-
tice, tends to emphasize sensitivity (i.e. the yield) more than
specificity. High specificity is important in cutting the costs of
expensive technology and preventing the over-use of clinical
services. In Finland the test positivity rate was low, i.e. the
specificity was high compared to some other breast cancer
screening programmes (Day & Miller, 1988). Further im-
provements in specificity can be obtained with more exper-
ience, because large differences were found in regional false
positivity rates with only a minor correlation to sensitivity by
region.
So far, most screening programmes have reported the
prevalence of disease detected at the first round to be about
0.6% (Day & Miller, 1988). This is higher than 0.4% in
Finland. The difference is partly due to the low risk of breast
cancer in Finland (Hakulinen et al., 1986). The ratio of
screening prevalence to incidence (2.4) indicates that the
screening mammography identified cases which would get
diagnosed by the routine clinical practice in the average of
the next 2.4 years if no screening were carried out. This is
smaller than estimated elsewhere (Day & Miller, 1988;
Andersson et al., 1988; Chamberlain et al., 1988), and the
fact remains that the sensitivity of the screening test was
probably relatively low. On the other hand, there remains the
possibility that not all the screen detected lesions diagnosed
as malignant would have surfaced clinically even if left un-
treated. In fact, the cancers diagnosed in an area with high
screening prevalence, were analysed by flow cytometry (Kalli-
oniemi et al., 1988). It was found that the average malig-
nancy rate was low and it was less than for cancers
diagnosed among 5 year survivors of clinically detected
breast cancer (Kallioniemi et al., 1989).
The ratio of risk of breast cancer diagnosed in the invited
cohorts to that among those not invited was only 1.6, clearly
less than the ratio (2.4) of screening prevalence to the inci-
dence in years preceeding the programme. This is a minimum
estimate because the cases of breast cancer among those
invited and diagnosis through normal clinical practice (inter-
nal cases) could not be distinguished from the cases diag-
nosed among those not invited. The estimate 1.6 describes
the programme and the estimate 2.4 that of the screening test
as applied within the policy. The difference is mainly due to
the nonattendance and the rapid spread of mammography as
case finding method or clinical service in Finland. Also some
municipalities have chosen to have mass screening for breast
cancer based on mammography but not carried out by the
Finnish Cancer Society. The effect of a public health screen-
ing policy may remain low if the service is commonly avail-
able for those not invited and if the attendance remains low.
This may be true rather for mammography (Andersson et al.,
1988) than for pap-test for which an organised screening
programme, a public health policy, is clearly superior over a
spontaneous use of services (Hakama et al., 1985).
The Finnish experience from the two first years of screen-
ing for breast cancer as a public health policy shows that the
programme was technically feasible, the attendance rate was
very high, the programme satisfactorily followed the experi-
mental design, and the health authorities were rapidly in-
formed of the results in terms of process indicators.
More generally, the Finnish experience demonstrates the
difference between a limited scale randomised preventive
trial, and a public health policy. It is likely that the effect-
iveness of the latter falls short of that derived from trials. It
may be especially difficult in a public policy programme to
obtain quality in taking, processing, and reading of the
mammogram similar to that in trials, which results in poor
sensitivity. On the other hand, routine pathology may be
inexperienced to assess the malignancy of small preclinical
lesions of the breast, resulting in overdiagnosis of cancer. It
is therefore important to design any public health policy
sufficiently rigorously so that its advantages and disadvan-
tages can be evaluated without bias. Finally, the Finnish
experience demonstrates that the experimental design can and
should be applied not only in clinical and preventive medi-
cine as randomised trials, but also to public health policy.
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